Emmanuelle Charpentier and Jennifer Doudna just received a few hours ago the Nobel prize in Chemistry 2020 for “the development of a method of genome editing”, namely their 2012 discovery of the CRISPR/Cas9 genetic scissors which basically enables to “cut and paste” DNA. This scientific discovery has fueled an unprecedented biotechnology development in the past 8 years. When we started to analyze the genome editing patent landscape in Spring 2014, there were only 96 patent families(*) in our records in relation with CRISPR. We have now more than 7400 in our latest records – and adding an average of 200 more every month in 2020. What does this data tell us on who has taken advantage in engineering new life sciences solutions out of this amazing scientific discovery, now confirmed worth a Nobel Prize?
Continue readingTag: landscape
Myths and realities on DuPont CRISPR assets
On the agriculture side, IAM just published this week some basic quantitative data analytics spotting DuPont as the leader in CRISPR patent assets. The IAM interview also highlighted some questions about the licensing position of DuPont in the CRISPR patent battle. This was quite surprising to read for us as this information has been publicly known since 2014 and regularly compiled in both our patent and licensing landscapes. Let’s take a closer scrutiny into the DuPont CRISPR assets. In our monitoring of licensing data since 2014, we have actually spotted DuPont Pioneer as one of the earliest player to position their licensing-in in a very strategic way:
April 2017 – CRISPR update
The CRISPR patent landscape kept on developing since February with more than 100 new patent publications in the past two months. We have now searched, reviewed and categorized 1340 patent families in our latest CRISPR patent analytics data set. Continue reading
Will the CRISPR patent landscape soon move to a one-stop license shopping?
The past 24 hours have brought new light and significant moves in the complex CRISPR patent landscape.
First (that was in European time zone!), our CRISPR expert Fabien Palazzoli celebrated the 1000th CRISPR patent family extraction out of the worldwide published patent databases. Our next monthly update will actually feature more than 1050 classified and categorized CRISPR patent families – more than 10 times the initial set of our first landscape release back in summer 2014!
CRISPR patent analytics – July 2016 update
From January to July 2016, our CRISPR patent monitoring set has almost doubled, from 489 to 787 published patent families. We now search, review and classify them on a monthly basis to stay up to date, watching for the latest technology coverage and application developments as can be derived from the individual patent claims.
Zoom on CAR-T in the CRISPR landscape
The CRISPR technology has a wide range of target applications, from agronomy to medicine. As we celebrate the 2nd birthday of CRISPR patent analytics services at IPStudies and the 4th year of the CRISPR-Cas9 invention, a few application areas show an increasing competitive activity in the landscape. On CAR-T (chimeric antigen receptor T) cell immunotherapy, we now find more than twenty patent applications in the CRISPR landscape. As could be expected from their marketing/communication, a number of pharmaceutical players and CRISPR technology development pioneers have actively positioned their IP in that domain, namely:
CRISPR patent analytics – April 2016 update
For the first quarter of 2016, we have added another 105 patent families to our CRISPR patent monitoring set. The CRISPR patent landscape keeps on growing steadily, with on average one new CRISPR patent family publication every day.
Our updated claim coverage analysis confirms the trends and facts we’ve reported in our detailed January 2016 patent landscape. 
Less licensing deals have been announced in the past few months, as the whole industry is watching for USPTO updates on the PTAB interference between two of the pioneering patent filings. More qualitative financial analysts are also now monitoring the outcome of this dispute, after the first successful CRISPR IPO (NASDAQ:EDIT) by Editas, a licensee of the pioneering Broad Institute patents, and the early April announcement of its own IPO filing by rival Intellia, a licensee of the pioneering University of California patent. In Europe, the CRISPR patent landscape is just as uncertain, with multiple (many anonymous – “strawman”) oppositions filed on the first granted patents.
While the uncertainty surrounding the licensing of the core technology patents is getting most media and business attention currently, the next rounds are already taking shape behind this main scene, with near 600 silent patent families claiming their own exclusive share of technology improvements, design-around attempts, and a myriad of specific application developments. There will be further disputes, settlements, and maybe even patent pools in the CRISPR era. The whole data is there, in multiple patent offices and databases – at IPStudies, we search, retrieve, sort and classify this data set to facilitate the CRISPR technology and competition watch for our customers: for more information on our patent landscape and patent monitoring services, check our CRISPR patent analytics offering or send us your inquiry through our contact form.
10 facts from the January 2016 CRISPR patent landscape
Our quarterly CRISPR patent landscape is now available. For this first release in 2016, we have included the latest business and technology developments, such as licensing deals information and a fully revisited breakdown of the functional and technical claim coverage. Our genomics expert Dr. Fabien Palazzoli has identified 489 CRISPR patent families out from worlwide patent registers, and systematically reviewed them down to individual claim wording to classify them into our unique, worldwide, independent CRISPR patent database.
In the meanwhile, facts and opinion papers around the Broad-Berkeley USPTO patent interference have been overloading our news monitoring capacity in the past 4 weeks… but that’s just about 2 pioneering families in the whole landscape. Here are 10 new facts out of the latest IPStudies CRISPR patent analytics – 489 CRISPR patent families as of January 2016:
Genome editing applications – Brussels – Feb 3-4, 2016
IPStudies will be attending the next Genome Editing Applications event in Brussels, now postponed to 3 – 4 February 2016.
A number of companies identified in our CRISPR patent landscape will be speaking there, such as CRISPR Therapeutics (TJ Cradick), Cellectis (Philippe Duchateau), AstraZeneca (Lorenz Mayr), Janssen R&D (Ines Royaux), Novartis (Anett Ritter), Cellecta (Paul Diehl), Merck & Co (Myung Shin), Precision Biosciences (Victor Bartsevitch), as well as instutional applicants such as the Technical University of Denmark, the Netherlands Cancer Institute, Duke University, Wellcome Trust Sanger Institute, and Royal Holloway-University of London.
The event also features a dedicated, interactive evening seminar, discussion and dinner on Intellectual Property and Business Strategy Landscape of Genome Editing Technologies, to be lead by Dr. Philip Webber from Dehns (UK Patent and Trade Mark Attorneys). More information can be found here.
For those attending, we invite you to take this opportunity to meet our head of biotech IP analytics, Dr. Fabien Palazzoli – ask a demo of our interactive CRISPR patent landscape for genome editing R&D/IP positioning! Our free sample can be downloaded here.
US inventor veterans at Intellectual Ventures are inventing around CRISPR gene editing
As both patent analysts and strategists, we like to look into the “weak signals” hidden behind the main trends of our landscapes, such as emerging design around solutions, original applications and new unexpected players entering the field.
In our latest update of our CRISPR patent landscape, we were surprised to discover a PCT patent application from a couple of senior inventors from Nathan Myhrvold’s team at Intellectual Ventures.
Continue reading